Research Into the Effect of a Clot-dissolving Agent and Its Inhibitor

Suspended

Phase N/A Results N/A

Summary of Purpose

Single-chain urokinase-type plasminogen activator (pro-urokinase) is a highly effective thrombolytic drug. At pharmacologic concentrations however, pro-urokinase is converted to urokinase - a non specific thrombolytic, limiting its therapeutic use. Mutant pro-urokinase (M5) is more stable and its conversion to urokinase is inhibited by C1-inhibitor. The primary objectives of the study are: - To assess...

Read More →

Trial Milestones

The following dates are available for this trial. Trial information last updated on 9 January 2015.

1 Sep 2015 24 Sep 2012 1 Dec 2015 1 Dec 2015 1 Jan 2015 Unavailable
Start Date First Received 1st Completion Completion Verification Results

Trial Basics

Conditions

Sponsors

Trial Design

  • Observation: Cohort
  • Perspective: Prospective
  • Sampling: Non-Probability Sample

Contacts

  • Koos Burggraaf, MD, PhD